List of Zepatier drug patents

Zepatier is owned by Merck Sharp Dohme.

Zepatier contains Elbasvir; Grazoprevir.

Zepatier has a total of 2 drug patents out of which 0 drug patents have expired.

Zepatier was authorised for market use on 28 January, 2016.

Zepatier is available in tablet;oral dosage forms.

Zepatier can be used as treatment of patients infected with hepatitis c virus.

The generics of Zepatier are possible to be released after 04 May, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7973040 MERCK SHARP DOHME Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Jul, 2029

(6 years from now)

US8871759 MERCK SHARP DOHME Inhibitors of hepatitis C virus replication
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 9, 2024

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of patients infected with hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in